X-Zell
Singapore, Singapore· Est.
Same‑day, multiplex digital cytology platform for fast, high‑content cancer diagnostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Same‑day, multiplex digital cytology platform for fast, high‑content cancer diagnostics.
Oncology
Technology Platform
Patented Cryoimmunostaining Suite with cryofixation, eight‑channel multiplex immunofluorescence, and high‑speed digital imaging on an automated hybrid microscope.
Opportunities
Expansion into EU and US markets with reimbursement support, and development of AI‑driven image analysis to enhance diagnostic value.
Risk Factors
Regulatory clearance timelines, adoption barriers in legacy pathology labs, and competition from established digital pathology vendors.
Competitive Landscape
Competes with Roche VENTANA, Leica Biosystems, and Philips, but differentiates through integrated cryofixation‑based multiplex cytology and same‑day digital workflow.